Clinical Trial Update: Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of encorafenib and cetuximab as neoadjuvant therapy for localized colon or upper rectal cancer with BRAF V600E…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Encorafenib (encorafenib)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Colorectal Cancer, BRAF V600E Mutation Positive | Phase 2 | Status: RECRUITING